[Documento de consenso de la Sociedad Española de Obstetricia y Ginecologia (SEGO) y el Comité Español Interdisciplinario para la Prevención Vascular (CEIPV). Ventana de oportunidad: prevención del riesgo vascular en la mujer. Resultados adversos del embarazo y riesgo de enfermedad vascular.]
María Goya, Marta Miserachs, Anna Suy Franch, Jorge Burgos, María de la Calle, Carlos Brotons, Mar Castellanos, Olga Cortés Rico, Ángel Díaz Rodriguez, Roberto Elosúa, María Del Mar Freijo, María González Fondado, Manuel Gorostidi, María Grau, Antonio M Hernández Martínez, Carlos Lahoz, Nuria Muñoz-Rivas, Vicente Pallares-Carratalá, Juan Pedro-Botet, Enrique Rodilla, Enrique Goya, Miguel Ángel Royo Bordonada, Rafael Santamaría, Mónica Torres Fonseca, Aina Velescu, Alberto Zamora, Pedro Armario
{"title":"[Documento de consenso de la Sociedad Española de Obstetricia y Ginecologia (SEGO) y el Comité Español Interdisciplinario para la Prevención Vascular (CEIPV). Ventana de oportunidad: prevención del riesgo vascular en la mujer. Resultados adversos del embarazo y riesgo de enfermedad vascular.]","authors":"María Goya, Marta Miserachs, Anna Suy Franch, Jorge Burgos, María de la Calle, Carlos Brotons, Mar Castellanos, Olga Cortés Rico, Ángel Díaz Rodriguez, Roberto Elosúa, María Del Mar Freijo, María González Fondado, Manuel Gorostidi, María Grau, Antonio M Hernández Martínez, Carlos Lahoz, Nuria Muñoz-Rivas, Vicente Pallares-Carratalá, Juan Pedro-Botet, Enrique Rodilla, Enrique Goya, Miguel Ángel Royo Bordonada, Rafael Santamaría, Mónica Torres Fonseca, Aina Velescu, Alberto Zamora, Pedro Armario","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>This document summarises the evidence regarding the association between adverse pregnancy outcomes (APOs), such as hypertensive disorders, preterm birth, gestational diabetes, fetal growth defects (small for gestational age and/or fetal growth restriction), placental abruption, fetal loss, and the risk that a pregnant individual in developing vascular risk factors (VR) that may lead to future vascular disease (VD): coronary heart disease, stroke, peripheral vascular disease, and heart failure. Furthermore, this document emphasises the importance of recognising APOs when assessing VR in women. A history of APOs serves as a sufficient indicator for primary prevention of VD. In fact, adopting a healthy diet and increasing physical activity among women with APOs, starting during pregnancy and/or postpartum, and maintaining it throughout life are significant interventions that can reduce VR. On the other hand, breastfeeding can also reduce the future VR of women, including a lower risk of mortality. Future studies evaluating the use of aspirin, statins, and metformin, among others, in women with a history of APOs could strengthen recommendations regarding pharmacotherapy for primary prevention of VD in these patients. Various healthcare system options exist to improve the transition of care for women with APOs between different healthcare professionals and implement long-term VR reduction strategies. One potential process could involve incorporating the fourth-trimester concept into clinical recommendations and healthcare policies.</p>","PeriodicalId":94199,"journal":{"name":"Revista espanola de salud publica","volume":"97 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista espanola de salud publica","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
This document summarises the evidence regarding the association between adverse pregnancy outcomes (APOs), such as hypertensive disorders, preterm birth, gestational diabetes, fetal growth defects (small for gestational age and/or fetal growth restriction), placental abruption, fetal loss, and the risk that a pregnant individual in developing vascular risk factors (VR) that may lead to future vascular disease (VD): coronary heart disease, stroke, peripheral vascular disease, and heart failure. Furthermore, this document emphasises the importance of recognising APOs when assessing VR in women. A history of APOs serves as a sufficient indicator for primary prevention of VD. In fact, adopting a healthy diet and increasing physical activity among women with APOs, starting during pregnancy and/or postpartum, and maintaining it throughout life are significant interventions that can reduce VR. On the other hand, breastfeeding can also reduce the future VR of women, including a lower risk of mortality. Future studies evaluating the use of aspirin, statins, and metformin, among others, in women with a history of APOs could strengthen recommendations regarding pharmacotherapy for primary prevention of VD in these patients. Various healthcare system options exist to improve the transition of care for women with APOs between different healthcare professionals and implement long-term VR reduction strategies. One potential process could involve incorporating the fourth-trimester concept into clinical recommendations and healthcare policies.